Trevi Therapeutics (TRVI) EBT (2018 - 2026)
Trevi Therapeutics' quarterly EBT came in at -$13.2 million in Q1 2026, down 27.64% year-on-year from -$18.3 million in Q1 2025, and down 58.57% quarter-over-quarter from -$8.3 million in Q4 2025.
Trevi Therapeutics has reported EBT for 9 years, with the latest figure at -$13.2 million in Q1 2026.
- For the quarter ending Q1 2026, EBT fell 27.64% year-over-year to -$13.2 million; the trailing twelve-month figure through Mar 2026 stood at -$45.7 million (up 3.59% YoY), and the FY2025 full-year result was -$42.8 million, up 10.68% from the prior year.
- EBT for Q1 2026 stood at -$13.2 million, down from -$8.3 million in the prior quarter.
- The five-year high for EBT was -$5.5 million in Q4 2022, with the low at -$13.3 million in Q3 2024.
- Average EBT over 5 years is -$9.5 million, with a median of -$8.3 million recorded in 2025.
- Year-over-year, EBT soared 35.2% in 2022 and plunged 72.26% in 2024.
- Tracing TRVI's EBT over 5 years: stood at -$5.5 million in 2022, then tumbled by 41.23% to -$7.8 million in 2023, then slumped by 46.08% to -$11.4 million in 2024, then increased by 26.91% to -$8.3 million in 2025, then slumped by 58.57% to -$13.2 million in 2026.
- The last three EBT figures came in at -$13.2 million (Q1 2026), -$8.3 million (Q4 2025), and -$11.8 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -2.99 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -19.60 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -15.31 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.25 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -3.18 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 831.20 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 221.65 Mn |
| 10 | Trevi Therapeutics | 2.02 Bn | 1.85 Bn | - | -13.21 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -13.21 Mn |
| Dec 31, 2025 | -8.33 Mn |
| Sep 30, 2025 | -11.82 Mn |
| Jun 30, 2025 | -12.32 Mn |
| Mar 31, 2025 | -10.35 Mn |
| Dec 31, 2024 | -11.40 Mn |
| Sep 30, 2024 | -13.27 Mn |
| Jun 30, 2024 | -12.36 Mn |
| Mar 31, 2024 | -10.91 Mn |
| Dec 31, 2023 | -7.80 Mn |
| Sep 30, 2023 | -7.71 Mn |
| Jun 30, 2023 | -7.18 Mn |
| Mar 31, 2023 | -6.41 Mn |
| Dec 31, 2022 | -5.53 Mn |
| Sep 30, 2022 | -8.27 Mn |
| Jun 30, 2022 | -8.06 Mn |
| Mar 31, 2022 | -7.33 Mn |
| Dec 31, 2021 | -8.53 Mn |
| Sep 30, 2021 | -7.25 Mn |
| Jun 30, 2021 | -9.80 Mn |
| Mar 31, 2021 | -8.39 Mn |
| Dec 31, 2020 | -9.51 Mn |
| Sep 30, 2020 | -7.39 Mn |
| Jun 30, 2020 | -7.40 Mn |
| Mar 31, 2020 | -8.48 Mn |
| Dec 31, 2019 | -6.54 Mn |
| Sep 30, 2019 | -7.37 Mn |
| Jun 30, 2019 | -7.35 Mn |
| Mar 31, 2019 | -4.81 Mn |
| Dec 31, 2018 | -6.03 Mn |
| Sep 30, 2018 | -5.68 Mn |
| Jun 30, 2018 | -4.88 Mn |
| Mar 31, 2018 | -4.08 Mn |